R01HL164571

Exercise Pressor Reflex in Peripheral Artery Disease: Roles of Flow Limitation and Reperfusion - Project Summary/Abstract

Our goal is to identify the mechanisms responsible for cardiovascular disability in Peripheral Artery Disease (PAD) and to examine therapies that will reduce the impact of these pathophysiologic processes. We have demonstrated that the Exercise Pressor Reflex (EPR) during leg exercise is exaggerated in PAD patients. The mechanisms for the exaggerated EPR in PAD patients have not been examined thoroughly.

Utilizing both human and animal studies, we propose to examine the roles of blood flow restriction (BFR) and ischemia-reperfusion (IR) stress in inducing the exaggerated EPR. We anticipate that a blockade of acid sensing ion channels (ASICs) with amiloride will reduce the exaggerated EPR and enhance the walking tolerance in PAD patients.

Aim 1: Determine the role of BFR in inducing the exaggerated EPR in PAD. We hypothesize that BFR leads to a greater H+/lower pH in the interstitium of exercising muscles and thereby accentuates the EPR via stimulating ASICs. We propose to employ BFR in healthy subjects to simulate the BFR in PAD. We speculate that BFR will augment the EPR in the placebo trial and amiloride will reduce the EPR and increase exercise time/load under BFR condition. We also speculate that amiloride will play the same beneficial role in PAD patients. In animal studies, we speculate that BFR by femoral artery occlusion will increase interstitial H+/decrease pH, thereby exaggerating the EPR via ASIC subtype 3 (ASIC3), and prolonged occlusion will upregulate ASIC3 expression in muscle afferent nerves of PAD.

Aim 2: Determine the role of IR in inducing the exaggerated EPR in PAD. We hypothesize that IR contributes to the exaggerated EPR in PAD and amiloride reduces the exaggerated EPR induced by IR stress via blocking ASICs. Healthy subjects will perform plantar flexion exercise under free flow conditions and after 20 minutes of ischemia followed by 20 minutes of reperfusion. We speculate that IR stress will accentuate the EPR. PAD patients before and after leg revascularization will also perform plantar flexion exercise. We speculate that amiloride will improve the EPR and increase exercise time/load in subjects after IR stress and in PAD patients with revascularization. In animal studies, we will examine the EPR in IR rats at different time courses and speculate that in IR rats, satisfactory reperfusion will alleviate the EPR and the pressor response induced by activation of afferent nerves' ASIC3.

Aim 3: Determine the effects of ASIC on exercise ability in PAD and fundamental mechanisms. We speculate that amiloride will decrease the pressor response to walking and increase the claudication onset time and walking distance/time in PAD patients. In animal studies, we speculate that the exaggerated EPR induced by IR will be attenuated in ASIC3 knockout rats. We will compare the protein levels of ASIC3 and its current response in muscle afferent neurons between IR rats at different time courses and their counterparts serving as controls. We speculate that ASIC3 expression and its current response in muscle afferent neurons will be amplified during the initiating IR stage and the effects of IR will be reduced by ASIC3 knockout or with sufficient time of reperfusion.

Pennsylvania State University

TO FOSTER HEART AND VASCULAR RESEARCH IN THE BASIC, TRANSLATIONAL, CLINICAL AND POPULATION SCIENCES, AND TO FOSTER TRAINING TO BUILD TALENTED YOUNG INVESTIGATORS IN THESE AREAS, FUNDED THROUGH COMPETITIVE RESEARCH TRAINING GRANTS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.

93.837 - Cardiovascular Diseases Research

National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]

Hershey, Pennsylvania 170332360 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 286% from $809,121 to $3,122,952.